Document:

EX-10.26

 Exhibit 10.26 

ROIVANT SCIENCES LTD. 

2021 EQUITY INCENTIVE PLAN 

1. GENERAL. 

(a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. 

(b) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options,
(ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, and (vi) Other Stock Awards. 

(c) Purpose. The Plan, through the granting of Awards, is intended to help the Company and its Affiliates secure and retain the
services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the
Common Shares. 
 2. ADMINISTRATION. 

(a) Administration by Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee
or Committees, as provided in Section 2(c). 
 (b) Powers of Board. The Board will have the power, subject to, and within
the limitations of, the express provisions of the Plan: 
 (i) To determine (A) who will be granted Awards; (B) when and
how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Shares under
the Award; (E) the number of Common Shares subject to, or the cash value of, an Award; (F) whether, to what extent and under what circumstances Awards may be settled or exercised in cash, Common Shares, other Awards, other property, net
settlement, or any combination thereof, or canceled, forfeited or suspended, and the method or methods by which Awards may be settled, exercised, canceled, forfeited or suspended; (G) whether, to what extent and under what circumstances cash,
Common Shares, other Awards, other property and other amounts payable with respect to an Award under the Plan shall be deferred either automatically or at the election of the holder thereof or of the Board; and (H) the Fair Market Value
applicable to an Award. 
 (ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke
rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or
expedient to make the Plan or Award fully effective. 
 (iii) To settle all controversies regarding the Plan and Awards granted
under it. 

 (iv) To accelerate, in whole or in part, the time at which an Award may be exercised
or vest (or at which cash or Common Shares may be issued). 
 (v) To suspend or terminate the Plan at any time. Except as otherwise
provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection
(viii) below. 
 (vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation,
by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive
Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. Except as otherwise provided in the Plan or an Award
Agreement, no amendment of the Plan will materially and adversely impair a Participant’s rights under an outstanding Award unless (A) the Company requests the consent of the affected Participant and (B) such Participant consents in
writing. 
 (vii) To submit any amendment to the Plan for shareholder approval, including, but not limited to, amendments to the
Plan intended to satisfy the requirements of (A) Section 422 of the Code regarding Incentive Stock Options or (B) Rule 16b-3. 

(viii) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but
not limited to, amendments to provide terms more favorable to a Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided, however, that
a Participant’s rights under any Award will not be materially and adversely impaired by any such amendment unless (A) the Company requests the consent of the affected Participant and (B) such Participant consents in writing.
Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially and
adversely impair the Participant’s rights and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant’s consent (I) to maintain the
qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (II) to change the terms of an Incentive Stock Option, if such change results in impairment of the Stock Award solely because it impairs the
qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (III) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (IV) to
comply with other applicable law or listing requirements. 
 (ix) Generally, to exercise such powers and to perform such acts as the
Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. 

  
 2 

 (x) To adopt such procedures and sub-plans
as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that, Board approval will not be necessary for immaterial
modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). 

(xi) To effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike
price of any outstanding Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award, (3) Restricted Stock Unit Award, (4) Other
Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of Common Shares as the cancelled Stock Award
and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting principles. 

(xii) To make any other determination and take any other action that the Board deems necessary or desirable for the administration of
the Plan and due compliance with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations. 

(c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or Committees.
If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in the Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of
administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the authority to concurrently administer the Plan
with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. 
 (d) Delegation to
an Officer. To the extent permitted under applicable law, the Board may delegate to one (1) or more Officers some or all of its authority under the Plan, including the authority to (i) designate Employees who are not Officers to be
recipients of Stock Awards under the Plan and the terms of such Stock Awards, and (ii) determine the number of Common Shares to be subject to such Stock Awards granted to such Employees; provided, however, that the Board
resolutions regarding such delegation will specify the total number of Common Shares that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will
be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board for such applicable Stock Award, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate
authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to clause (iii) of the definition thereof. 

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board (or a Committee or
an Officer to whom authority has been delegated by the Board pursuant to Section 2(c) or Section 2(d), as applicable) will not be subject to review by any person and will be final, binding and conclusive on all persons. 

  
 3 

 3. SHARES SUBJECT TO THE
PLAN. 
 (a) Share Reserve. Subject to Section 9(a) relating to Capitalization Adjustments, and the
following sentence regarding the annual increase, the aggregate number of Common Shares that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed [•]1
Common Shares (the “Share Reserve”). In addition, subject to Section 9(a), the total number of Common Shares available for issuance pursuant to the Share Reserve under the Plan shall be increased on the first day of each
fiscal year of the Company following the Effective Date (and prior to the termination of the Plan) in an amount equal to the lesser of (i) 5% of the Common Shares outstanding as of the last day of the immediately preceding fiscal year of the Company
and (ii) such number of Common Shares as determined by the Board in its discretion. Common Shares issued in respect of Substitute Awards will not reduce the number of Common Shares available for issuance from the Share Reserve. 

(b) Reversion of Shares to the Share Reserve. If a Stock Award issued against the Share Reserve or any portion of such Stock
Award (i) expires or otherwise terminates without all of the Common Shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than Common Shares), such expiration,
termination or settlement will not reduce (or otherwise offset) the number of Common Shares that may be available for issuance from the Share Reserve. If any Common Shares issued pursuant to a Stock Award issued against the Share Reserve are
forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such Common Shares in the Participant, then the Common Shares that are forfeited or repurchased will revert to and again
become available for issuance under the Share Reserve. Any Common Shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again
become available for issuance under the Share Reserve. 
 (c) Incentive Stock Option Limit. Subject to the provisions
of Section 9(a) relating to Capitalization Adjustments and approval of the Plan by the Company’s shareholders, the aggregate maximum number of Common Shares that may be issued pursuant to the exercise of Incentive Stock Options will be
[•]2 Common Shares. If the Plan is not approved by the Company’s shareholders, no Incentive Stock Options may be granted under the Plan. 

 

	1 	 Note to Draft: The initial Share Reserve to be equal to 10% of the aggregate outstanding shares of the
Company as of the closing date of the business combination transaction (the “Closing Date”). As of the Closing Date, no future awards will be granted under the Company’s existing equity incentive plans (but awards then-outstanding
under such existing equity-incentive plans will remain outstanding in accordance with their terms, subject to the adjustment provisions in the BCA). 

	2 	 Note to Draft: To equal to the initial Share Reserve or a lesser amount to be determined by the Board
prior to the adoption of the Plan. 

  
 4 

 (d) Limitation on Compensation Paid to
Non-Employee Directors. The maximum number of Common Shares subject to any Awards granted under the Plan or otherwise during any one fiscal year to any Non-Employee
Director, taken together with any cash fees paid by the Company to such Non-Employee Director during such fiscal year for service on the Board, will not exceed $750,000 (or $1,000,000 for such Non-Employee Director’s first fiscal year of service on the Board) in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting
purposes). 
 (e) Source of Shares. The securities issuable under the Plan will be authorized but unissued or
reacquired Common Shares, including Common Shares repurchased by the Company on the open market or otherwise. 
 4.
ELIGIBILITY. 
 (a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to
employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to
Employees, Directors and Consultants. 
 (b) Ten Percent Shareholders. A Ten Percent Shareholder will not be granted an
Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. 

5. PROVISIONS RELATING TO OPTIONS AND STOCK
APPRECIATION RIGHTS. 
 Each Option or SAR will be in such form and will contain such terms and conditions
as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for Common
Shares purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an
Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Stock Award Agreement
will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions: 

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Shareholders, no Option or SAR will be exercisable
after the expiration of ten (10) years from the date of its grant or such shorter period specified in the Stock Award Agreement. 

(b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Shareholders and except in the case of
Substitute Awards, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Shares subject to the Option or SAR on the date the Stock Award is granted. 

  
 5 

 (c) Purchase Price for Options. The purchase price of Common Shares acquired
pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to
grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted
methods of payment are as follows: 
 (i) by cash, check, bank draft or money order payable to the Company; 

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the
Common Shares subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; 

(iii) by delivery to the Company (either by actual delivery or attestation) of Common Shares; 

(iv) if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce
the number of Common Shares issuable upon exercise by the largest whole number of Common Shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or other
payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole Common Shares to be issued. Common Shares will no longer be subject to an Option and will not
be exercisable thereafter to the extent that (A) Common Shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) Common Shares are delivered to the Participant as a result of such exercise,
and (C) Common Shares are withheld to satisfy tax withholding obligations; or 
 (v) in any other form of legal consideration
that may be acceptable to the Board. 
 (d) Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant
must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount
equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of Common Shares equal to the number of Common Share equivalents in which the Participant is vested under such SAR, and with respect
to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Share equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution
may be paid in Common Shares, in cash, in any combination of the two or in any other form of consideration, as determined by the Board. 

  
 6 

 (e) Transferability of Options and SARs. The Board may, in its sole
discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs
will apply: 
 (i) Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of
descent and distribution (or pursuant to subsections (ii), (iii), and (iv) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is
not prohibited by applicable tax or securities law. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration. 

(ii) Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be
transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2). If an Option
is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 
 (iii)
Certain Trusts. Subject to the approval of the Board or a duly authorized Officer and applicable law, an Option may be transferred to a trust if the Participant is considered to be the sole beneficial owner (determined under Section 671
of the Code and applicable state law) while the Option is held in the trust. The Participant and the trustee must enter into transfer and other agreements required by the Company. 

(iv) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by
delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive Common
Shares or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and
receive Common Shares or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with
the provisions of applicable law. 
 (f) Vesting Generally. The total number of Common Shares subject to an Option or SAR may
vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction
of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum
number of Common Shares as to which an Option or SAR may be exercised. 
 (g) Termination of Continuous Service. Except as
otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or
Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of
(i) the date three (3) months following the termination of the Participant’s Continuous Service (or such 

  
 7 

 
longer or shorter period specified in the applicable Stock Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after
termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. 

(h) Extension of Termination Date. If the exercise of an Option or SAR following the termination of the Participant’s
Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of Common Shares would violate the registration requirements under the Securities
Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post termination exercise period, as set forth in Section 5(g), after the
termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the
applicable Stock Award Agreement. In addition, unless otherwise provided in a Participant’s Stock Award Agreement, if the sale of any Common Share received upon exercise of an Option or SAR following the termination of the Participant’s
Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the
applicable post-termination exercise period, as set forth in Section 5(g), after the termination of the Participant’s Continuous Service during which the sale of the Common Share received upon exercise of the Option or SAR would not be in
violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. 

(i) Disability of Participant. Except as otherwise provided in the applicable Stock Award Agreement or other agreement between
the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to
exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer
or shorter period specified in the Stock Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or
her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. 
 (j) Death of
Participant. Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s
death or (ii) the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR
may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a
person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the date eighteen (18) months following the date of death (or such

  
 8 

 
longer or shorter period specified in the Stock Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the
Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate. 

(k) Termination for Cause. Except as explicitly provided otherwise in a Participant’s Stock Award Agreement or other
individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant’s termination of
Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR (as applicable) from and after the time of such termination of Continuous Service. 

(l) Automatic Exercise. If, as of the last day of the term of an Option or SAR, (i) the Fair Market Value of a Common Share
subject to the Option or SAR, as applicable, exceeds the aggregate exercise or strike price of the Option or SAR and (ii) the Participant has not previously exercised such Option or SAR, then the Option or SAR shall be deemed to have been
exercised by the Participant on such date (the “Automatic Exercise Date”), which such automatic exercise shall be made on a “net exercise” basis to cover the applicable exercise or strike price applicable to such
Option or SAR and any applicable tax withholding obligations; provided that, unless otherwise determined by the Board, this Section 5(l) shall not apply to any Option or SAR held by a Participant who has incurred a termination of
Continuous Service on or before the Automatic Exercise Date. 
 (m) Non-Exempt
Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for
any Common Shares until at least six (6) months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Change in Control, or (iii) upon the Participant’s retirement (as such term may be defined in the Participant’s Stock Award
Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised
earlier than six (6) months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an
Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a
non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this
Section 5(m) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements. 

  
 9 

 6. PROVISIONS OF STOCK AWARDS
OTHER THAN OPTIONS AND SARS. 
 (a) Restricted Stock
Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, Common Shares
underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii) evidenced by a certificate, which certificate
will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be
identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order
payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

(ii) Vesting. Common Shares awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in
accordance with a vesting schedule (including with respect to performance goals or other criteria) to be determined by the Board. 

(iii) Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company
may receive through a forfeiture condition or a repurchase right any or all of the Common Shares held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement. 

(iv) Transferability. Rights to acquire Common Shares under the Restricted Stock Award Agreement will be transferable by the
Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as determined by the Board in its sole discretion, so long as Common Shares awarded under the Restricted Stock Award Agreement remains subject
to the terms of the Restricted Stock Award Agreement. 
 (v) Dividends. A Restricted Stock Award Agreement may provide
that any dividends paid on Restricted Stock Awards will be subject to the same vesting and forfeiture restrictions as apply to the Common Shares subject to the Restricted Stock Award to which they relate. 

(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms
and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.
Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in such agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to
be paid by the Participant upon delivery of each Common Share subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each Common Share subject to a Restricted Stock Unit Award may be paid in any form
of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

  
 10 

 (ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the
Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award (including performance goals or other criteria) as it, in its sole discretion, deems appropriate. 

(iii) Termination of Participant’s Continuous Service. Except as otherwise provided in the applicable Restricted Stock
Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service. 

(iv) Payment. A Restricted Stock Unit Award may be settled by the delivery of Common Shares, their cash equivalent, any
combination thereof or in any other form of consideration, as determined by the Board. 
 (v) Additional Restrictions. At the
time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of Common Shares (or their cash equivalent) subject to a Restricted Stock Unit Award to a time
after the vesting of such Restricted Stock Unit Award. 
 (vi) Dividend Equivalents. Dividend equivalents may be credited in
respect of Common Shares covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional
Common Shares covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional Common Shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the
same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. 
 (c) Other Stock
Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Shares, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less
than 100% of the Fair Market Value of the Common Shares at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions
of the Plan, the Board will have sole and complete authority to determine the eligible Participants to whom and the time or times at which such Other Stock Awards will be granted, the number of Common Shares (or the cash equivalent thereof) to be
granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. 
 7. COVENANTS
OF THE COMPANY. 
 (a) Securities Law Compliance. The Company will seek to
obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell Common Shares upon exercise or vesting of the Stock Awards; provided, however,
that this undertaking will not require the Company to 

  
 11 

 
register under the Securities Act (or other applicable law) the Plan, any Stock Award or any Common Shares issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at
a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Shares under the Plan, the Company will be
relieved from any liability for failure to issue and sell Common Shares upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash
or Common Shares pursuant to the Award if such grant or issuance would be in violation of any applicable securities law. 
 (b) No
Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to
warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of
such Award. 
 8. MISCELLANEOUS. 

(a) Use of Proceeds from Sales of Common Shares. Proceeds from the sale of shares of Common Shares pursuant to Stock Awards will
constitute general funds of the Company. 
 (b) Corporate Action Constituting Grant of Awards. Corporate action constituting a
grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is
communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g.,
exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate
records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. 

(c) Shareholder Rights. Other than as provided for in Section 6(a) with respect to Restricted Stock Awards, no Participant
will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any Common Shares subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of Common
Shares under, the Award pursuant to its terms, and (ii) the issuance of the Common Shares subject to the Award has been entered into the books and records of the Company. 

(d) No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder
or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the
Company or an Affiliate to terminate (i) the employment of an Employee with or 

  
 12 

 
without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the
service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated or domiciled, as the case may
be. 
 (e) Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of
his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after
the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (i) make a corresponding reduction in the number of Common Shares subject to any portion of such Award that is scheduled to vest or become
payable after the date of such change in time commitment, and (ii) subject to the requirements of Section 409A of the Code, in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such
Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. 

(f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant) of
Common Shares with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the
Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be
treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 
 (g)
Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Shares under any Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and
experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone
or together with the purchaser representative, the merits and risks of exercising the Award, and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Shares subject to the Award for the
Participant’s own account and not with any present intention of selling or otherwise distributing the Common Shares. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) Common
Shares from the Common Shares issued or otherwise issuable to the Participant upon the exercise, vesting or settlement of the Participant’s Award has been registered under a then-effective registration statement under the Securities Act, or
(B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then-applicable securities laws. The Company may, upon advice of counsel to the
Company, place legends on share certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common
Shares. 

  
 13 

 (h) Withholding Obligations. The Company may, in its sole discretion, satisfy
any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding Common Shares from
the Common Shares issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no Common Shares are withheld with a value exceeding the maximum amount of tax required to be withheld by law (or such
lesser amount as may be necessary to avoid classification of the Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the
Participant; or (v) by such other method as may be acceptable to the Board. 
 (i) Electronic Delivery. Any reference
herein to a “written” agreement or document will include any agreement or document delivered electronically, publicly filed with the Securities Exchange Commission or posted on the Company’s intranet (or other shared electronic medium
controlled by the Company to which the Participant has access). 
 (j) Deferrals. To the extent permitted by applicable law,
the Board, in its sole discretion, may determine that the delivery of Common Shares or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for
deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is
still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following
the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 

(k) Compliance with Section 409A and Section 457A of the Code. Unless otherwise expressly
provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code and Section 457A of
the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code and Section 457A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A
of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary
for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in the Plan (and unless the Award Agreement specifically provides otherwise), if the Common Shares are publicly
traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any
amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six (6) months following the
date of such Participant’s “separation from service” or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any
amounts so deferred will be paid in a lump sum on the day after such six (6) month period elapses, with the balance paid thereafter on the original schedule. 

  
 14 

 (l) Clawback/Recovery. All Awards granted under the Plan will be subject to
recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise
required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or
appropriate, including but not limited to a reacquisition right in respect of previously acquired Common Shares or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback policy
will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar term) under any agreement with the Company or an Affiliate. 

9. ADJUSTMENTS UPON CHANGES IN COMMON SHARES;
OTHER CORPORATE EVENTS. 
 (a) Capitalization Adjustments. In the event of a
Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that
may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards (including, as appropriate, any
exercise price, threshold, target or maximum price measure, knock-in price measure or other share price measure applicable to any outstanding Stock Awards). The Board will make such adjustments, and its
determination will be final, binding and conclusive. 
 (b) Dissolution. Except as otherwise provided in the Stock Award
Agreement, in the event of a Dissolution of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding Common Shares not subject to a forfeiture condition or the Company’s right of repurchase) will
terminate immediately prior to the completion of such Dissolution, and the Common Shares subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact
that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to
repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the Dissolution is completed but contingent on its completion. 

(c) Change in Control. The following provisions will apply to Stock Awards in the event of a Change in Control unless otherwise
provided in the Stock Award Agreement or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the event of a Change in
Control, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the applicable Change in Control: 

(i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) to
assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the shareholders of the Company pursuant to the applicable Change in
Control); 

  
 15 

 (ii) arrange for the assignment of any reacquisition or repurchase rights held by
the Company in respect of Common Shares issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); 

(iii) accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be
exercised) to a date prior to the effective time of such Change in Control as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective date of the Change in Control), with
such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Change in Control; provided, however, that the Board may require Participants to complete and deliver to the Company a notice of
exercise before the effective date of a Change in Control, which exercise is contingent upon the effectiveness of such Change in Control; 

(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the
Stock Award; 
 (v) determine the level of attainment of any performance conditions applicable to any Stock Award; 

(vi) cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time
of the Change in Control, in exchange for such cash consideration, if any, as the Board, in its sole discretion, determines is appropriate; and 

(vii) cancel such Stock Award in exchange for a payment, in such form as may be determined by the Board equal to the excess, if any,
of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Change in Control, over (B) any exercise price payable by such holder in connection
with such exercise; provided that, this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the
holders of the Company’s Common Shares in connection with the Change in Control is delayed as a result of escrows, earn outs, holdbacks or any other contingencies, to the extent applicable, in accordance with Section 409A and 457A of the
Code. 
 The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The
Board may take different actions with respect to the vested and unvested portions of a Stock Award. 
 10. EFFECTIVE
DATE OF PLAN. 
 This Plan will become effective on the Effective Date. 

  
 16 

 11. PLAN TERM. 

The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will automatically terminate on the
day before the tenth (10th) anniversary of the Effective Date. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated. However, unless otherwise expressly provided in the Plan or in an applicable Award
Agreement, any Stock Award theretofore granted may extend beyond such date, and the authority of the Board to amend, alter, adjust, suspend, discontinue or terminate any such Stock Award, or to waive any conditions or rights under any such Stock
Award, and the authority of the Board to amend the Plan, shall extend beyond such date. 
 12. CHOICE OF
LAW. 
 To the extent that United States federal laws do not otherwise control, the Plan and all determinations made and
actions taken pursuant to the Plan shall be governed by the internal laws of the State of New York, and construed accordingly, except for those matters subject to The Companies Act, 1981 of Bermuda (as amended), which shall be governed by Bermuda
law, without giving effect to principles of conflicts of laws, and construed accordingly. 
 13. DATA
PROTECTION. 
 By participating in the Plan, the Participant hereby acknowledges the collection, use, disclosure and
processing of Personal Data provided by the Participant to the Company or any Affiliate, trustee or third party service provider, such as name, account information, social security number, tax number and contact information, for the Company’s
legitimate business purposes and as necessary for all purposes relating to the operation and performance of the Plan. These include, but are not limited to: 

(a) administering and maintaining Participant records; 

(b) providing the services described in the Plan; 

(c) providing information to future purchasers or merger partners of the Company or any Affiliate, or the business in which such
Participant works; and 
 (d) responding to public authorities, court orders and legal investigations, as applicable. 

The Company may share a Participant’s Personal Data with (i) Affiliates, (ii) trustees of any employee benefit trust,
(iii) registrars, (iv) brokers, (v) third party administrators of the Plan, (vi) third party service providers acting on the Company’s behalf to provide the services described above or (vii) regulators and others, as
required by law. 
 If necessary, the Company may transfer a Participant’s Personal Data to any of the parties mentioned above in any
country or territory that may not provide the same protection for the information as a Participant’s home country. Any transfer of a Participant’s Personal Data from the E.U. to a third country is subject to appropriate safeguards in the
form of EU standard contractual clauses (according to decisions 2001/497/EC, 2004/915/EC, 2010/87/EU) or applicable derogations provided for under applicable law. Further information on those safeguards or derogations can be obtained through, and
other questions regarding this Section 13 may be directed to [•]. 

  
 17 

 The Company will keep Personal Data for as long as necessary to operate the Plan or as
necessary to comply with any legal or regulatory requirements. 
 14. DEFINITIONS. 

As used in the Plan, the following definitions will apply to the capitalized terms indicated below: 

(a) “Affiliate” means, at the time of determination, each of the following: (i) any “parent” of
the Company, as such term is defined in Rule 405; (ii) any “subsidiary” of the Company, as such term is defined in Rule 405; and (iii) any other entity in which the Company or any of its Affiliates has a material equity interest or
control relationship unless otherwise designated by the Board. An entity will be deemed an Affiliate of the Company for purposes of this definition only for such periods as the requisite ownership or control relationship is maintained. The Board
will have the authority to determine the time or times at which “parent” or “majority-owned subsidiary” status is determined within the definitions set forth in Rule 405. 

(b) “Award” means a Stock Award. 

(c) “Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and
conditions of an Award. 
 (d) “Beneficial Owner” has the meaning ascribed to such term in Rule 13d-3 under the Exchange Act. 
 (e) “Board” means the Board of Directors
of the Company. 
 (f) “Capitalization Adjustment” means any change that is made in, or other events that
occur with respect to, the Common Shares subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, amalgamation, reorganization, recapitalization,
reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, reverse share split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. 
 (g) “Cause” will have the
meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events:
(i) such Participant’s willful failure substantially to perform his or her duties and responsibilities to the Company or deliberate violation of a Company policy; (ii) such Participant’s commission of (a) any act of fraud,
embezzlement, dishonesty or any other willful 

  
 18 

 
misconduct or gross negligence that has caused or is reasonably expected to result in material injury to the Company or (b) any felony; (iii) unauthorized use or disclosure by such
Participant of any proprietary information or trade secrets of the Company or any other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with the Company; or (iv) such Participant’s
willful breach of any of his or her obligations under any written agreement or covenant with the Company. The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the
Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any
determination of the rights or obligations of the Company or such Participant for any other purpose. 
 (h) “Change in
Control” means, unless otherwise expressly provided in any Award Agreement, the occurrence of any one or more of the following events: 

(i) any Person, other than (A) any employee plan established by the Company or any Subsidiary, (B) the Company
or any of its Affiliates, (C) an underwriter temporarily holding securities pursuant to an offering of such securities, or (D) an Entity owned, directly or indirectly, by shareholders of the Company in substantially the same proportions as
their ownership of the Company, is (or becomes, during any 12-month period) the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by
such Person any securities acquired directly from the Company or its Affiliates other than in connection with the acquisition by the Company or its Affiliates of a business) representing 50% or more of the total voting power of the shares of the
Company; provided that, the provisions of this subsection (i) are not intended to apply to or include as a Change in Control any transaction that is specifically excepted from the definition of Change in Control under subsection
(iii) below; 
 (ii) a change in the composition of the Board such that, during any 12-month period, the individuals who, as of the beginning of such period, constitute the Board (the “Existing Board”) cease for any reason to constitute a majority of the Board;
provided, however, that any individual becoming a member of the Board subsequent to the beginning of such period whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a
majority of the members of the Existing Board immediately prior to the date of such appointment or election shall be considered as though such individual were a member of the Existing Board; 

(iii) the consummation of a merger, amalgamation or consolidation of the Company with any other corporation or other
Entity, or the issuance of voting securities in connection with such a transaction pursuant to applicable stock exchange requirements; provided that, immediately following such transaction the voting securities of the Company outstanding
immediately prior thereto do not continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving Entity of such transaction or parent Entity thereof) 50% or more of the total voting power and
total fair market value of the Company’s stock (or, if the Company is not the surviving entity of such merger or consolidation, 50% or more of the total voting power and total 

  
 19 

 
fair market value of the stock of such surviving Entity or parent Entity thereof); and provided, further, that such a transaction effected to implement a recapitalization of the
Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the
Company or its Affiliates other than in connection with the acquisition by the Company or its Affiliates of a business) representing 50% or more of either the then-outstanding Common Shares or the combined voting power and total fair market value of
the Company’s then-outstanding voting securities shall not be considered a Change in Control; or 
 (iv) the sale
or disposition by the Company of all or substantially all of the Company’s assets in which any Person acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition
by such Person) assets from the Company that have a total gross fair market value equal to more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. 

Notwithstanding the foregoing, (A) no Change in Control shall be deemed to have occurred if there is consummated any transaction or series of integrated
transactions immediately following which the record holders of the Shares immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an Entity which owns substantially all of
the assets of the Company immediately prior to such transaction or series of transactions and (B) no Change in Control shall be deemed to have occurred upon the acquisition of additional control of the Company by any Person that is considered
to effectively control the Company. In no event will a Change in Control be deemed to have occurred if any Participant is part of a “group” within the meaning of Section 13(d)(3) of the Exchange Act that effects a Change in Control.
Notwithstanding the foregoing or any provision of any Award Agreement to the contrary, for any Award that provides for accelerated distribution on a Change in Control of amounts that constitute “deferred compensation” (as defined in
Section 409A of the Code), if the event that constitutes such Change in Control does not also constitute a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company’s assets
(in either case, as defined in Section 409A of the Code), such amount shall not be distributed on such Change in Control but instead shall vest as of such Change in Control and shall be distributed on the scheduled payment date specified in the
applicable Award Agreement, except to the extent that earlier distribution would not result in the Participant who holds such Award incurring interest or additional tax under Section 409A of the Code. 

(i) “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. 
 (j) “Committee” means the compensation committee of the Board, unless another
committee is designated by the Board. If there is no compensation committee of the Board and the Board does not designate another committee, references herein to the “Committee” shall refer to the Board. 

(k) “Common Shares” means the common shares of the Company. 

  
 20 

 (l) “Company” means Roivant Sciences Ltd., an exempted
limited company incorporated under the laws of Bermuda, with its registered office at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda or any successor to all or substantially all of its businesses by merger, amalgamation, consolidation,
purchase of assets, or otherwise. 
 (m) “Consultant” means any person, including an advisor, who is
(i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services (including any individual who has accepted an offer of service or consultancy from the Company or an Affiliate), or
(ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a
“Consultant” for purposes of the Plan. 
 (n) “Continuous Service” means that the
Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. Unless otherwise determined by the Board (or its delegate) in its sole discretion, (i) a change in
the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant (for example, a change in status from an Employee of the Company to a Consultant or Director of the Company) will not
terminate a Participant’s Continuous Service; provided that, there is otherwise no interruption or termination of the Participant’s service with the Company or such applicable Affiliate and (ii) if the Entity for which a
Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board (or its delegate) in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases
to qualify as an Affiliate. To the extent permitted by law, the Board (or its delegate), in its sole discretion, may determine whether Continuous Service will be considered interrupted and when Continuous Service will be considered terminated in the
case of (i) any approved leave of absence, including sick leave, military leave or any other personal leave or (ii) transfers between the Company, an Affiliate, or their successors or other change in the Entity for which the Participant
renders service. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms
of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. Notwithstanding the foregoing, with respect to any Award subject to Section 409A of the Code (and not exempt therefrom), a termination
of Continuous Service occurs when a Participant experiences a “separation of service” (as such term is defined under Section 409A of the Code). 

(o) “Director” means a member of the Board. 

(p) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve (12) months
as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(q) “Dissolution” means when the Company has completely wound up its affairs and dissolved in
accordance with the Companies Act 1981 of Bermuda. 

  
 21 

 (r) “Effective Date” means the [•]. 

(s) “Employee” means any person employed by the Company or an Affiliate (including any individual who has
accepted an offer of employment from the Company or an Affiliate). However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan. 

(t) “Entity” means a corporation, partnership, limited liability company or other 

entity. 
 (u)
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

(v) “Fair Market Value” means, as of any date, the value of the Common Shares determined as follows: 

(i) If the Common Shares are listed on any established stock exchange or traded on any established market, the Fair Market Value of a
Common Share will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Shares) on the date of
determination, as reported in a source the Board deems reliable. 
 (ii) Unless otherwise provided by the Board, if there is no
closing sales price for the Common Shares on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists. 

(iii) In the absence of such markets for the Common Shares, the Fair Market Value will be determined by the Board in good faith and in
a manner that complies with Sections 409A and 422 of the Code, as applicable. 
 (w) “Incentive Stock Option”
means an option granted pursuant to Section 5 of the Plan that is intended to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 

(x) “Non-Employee Director” means a Director who is not an Employee.

 (y) “Nonstatutory Stock Option” means any option granted pursuant to Section 5 of the Plan that does
not qualify as an Incentive Stock Option. 
 (z) “Officer” means a person who is an “officer” of
the Company or an Affiliate within the meaning of Rule 16a-1(f) under the Exchange Act. 

(aa) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase Common Shares granted
pursuant to the Plan. 

  
 22 

 (bb) “Option Agreement” means a written agreement between the
Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. 

(cc) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. 
 (dd) “Other Stock Award” means an award based in whole or in
part by reference to the Common Shares which is granted pursuant to the terms and conditions of Section 6(d). 
 (ee)
“Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. 

(ff) “Person” has the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in
Sections 13(d) and 14(d) thereof, including a “group” as defined in Section 13(d) thereof. 
 (gg)
“Personal Data” means (i) any data or information that relates to or is reasonably capable of being directly or indirectly associated with an identified or identifiable individual or household and (ii) any other
data or information that is otherwise considered “personal data,” “personal information,” “personally identifiable information,” or any term of comparable intent, under applicable laws or regulations relating to the
collection, use, transfer, deletion, protection or other processing of such data or information. 
 (hh)
“Plan” means this Roivant Sciences Ltd. 2021 Equity Incentive Plan, as it may be amended from time to time. 

(ii) “Restricted Stock Award” means an award of Common Shares which is granted pursuant to the terms and
conditions of Section 6(a). 
 (jj) “Restricted Stock Award Agreement” means a written agreement between
the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(kk) “Restricted Stock Unit Award” means a right to receive Common Shares which is granted pursuant to the
terms and conditions of Section 6(b). 
 (ll) “Restricted Stock Unit Award Agreement” means a written
agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the
Plan. 
 (mm) “Rule 16b-3” means Rule
16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time. 

(nn) “Rule 405” means Rule 405 promulgated under the Securities Act. 

  
 23 

 (oo) “Securities Act” means the Securities Act of 1933, as
amended. 
 (pp) “Stock Appreciation Right” or “SAR” means a right to receive the
appreciation on Common Shares that is granted pursuant to the terms and conditions of Section 5. 
 (qq) “Stock
Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will
be subject to the terms and conditions of the Plan. 
 (rr) “Stock Award” means any right to receive Common
Shares granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award. 

(ss) “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(tt) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. 
 (uu) “Substitute
Award” means an Award granted in assumption of, or in substitution for, an outstanding award previously granted by a company or other business acquired by the Company or with which the Company combines. 

(vv) “Ten Percent Shareholder” means a person who owns (or is deemed to own pursuant to Section 424(d) of
the Code) shares possessing more than 10% of the total combined voting power of all classes of shares of the Company or any Affiliate. 

  
 24EX-10.27

 Exhibit 10.27 

Execution Version 

STRICTLY CONFIDENTIAL 
 May 14, 2021

 Vivek Ramaswamy 
 Via Email 

Re: Amended and Restated Employment Agreement 
 Dear Vivek: 

This letter agreement (this “Agreement”), memorializes our mutual understanding regarding your continued employment with
Roivant Sciences, Inc., a Delaware corporation (the “Company”). This Agreement amends and restates, effective as of May 14, 2021 (the “Effective Date”), your prior employment agreement with the Company, dated
March 4, 2016 (the “Prior Agreement”). Reference is made in this Agreement to the letter agreement between you and the Company, dated March 30, 2021 (the “Letter Agreement”). 

1.    Position and Duties. Effective as of January 26, 2021 (the “Transition Date”), you
ceased serving as the Company’s Chief Executive Officer and transitioned to the role of Executive Chairman of the Company. Subject to the terms set forth in this Agreement and the Letter Agreement, on and following the Effective Date, you will
continue to be employed on a full-time basis by the Company as its Executive Chairman. In your role as Executive Chairman of the Company, you have had, and will continue to have, the authority, duties and responsibilities normally associated with
such position and assigned to you by the Board of Directors of the Company (the “Board”) from time to time, in each case which have been and will continue to be solely advisory in nature, including supporting the strategic
initiatives of the Company, serving as an ambassador for the Company by maintaining and fostering relationships with internal and external stakeholders (including employees, clients, investors, analysts, regulators and other government entities),
and providing the Board and the Company’s Chief Executive Officer with insight based on the depth of your industry experience and expertise and your historical knowledge of the Company’s business. In addition, you may serve as a director
or officer of one or more of the Company’s Affiliates, without further compensation. You will report to, and be subject to the direction of, the Board. You agree to perform the duties of your positions as may reasonably be assigned to you from
time to time by the Board consistent with your positions. Notwithstanding anything to the contrary herein, in your role as Executive Chairman, you have not had since the Transition Date, and you will not have on or following the Effective Date, any
final authority to make, implement or control any policy decisions for or on behalf of the Company or any of its Affiliates. While you are employed by the Company, without the prior approval of the Board, subject to Sections 3(d) and
3(e) below, (i) you may engage in business and provide services or advice to other businesses or entities (provided that, except as expressly set forth in clause (ii) below, any such business or entity is not engaged in
biotechnology or pharmaceuticals, does not constitute a Competitive Business (as defined below) and is not otherwise competitive with the Company), (ii) you may provide advice to any business or entity that is engaged in biotechnology or
pharmaceuticals (provided that you do not directly or indirectly receive any compensation in connection therewith and such business or entity does not constitute a Competitive Business and is not otherwise competitive with the Company) and
(iii) you may engage in civic, educational, political, fraternal, professional, charitable and community affairs and activities (provided that such affairs and activities are not competitive with the Company), in each case so long as
such services, advice, affairs or activities do not interfere with your duties and responsibilities under this Agreement (clauses (i) through (iii) collectively, the “Permitted Activities”). Under no circumstance shall you
engage in any activity, whether or not connected with your employment with the Company, which creates a conflict of interest between you, the Company or any of its Affiliates. Subject to Section 4 below, the Company retains the right to
terminate your employment at any time, including, without limitation, with or without notice and with or without Cause (as defined below). 

2.    Compensation and Benefits. During your employment, as compensation for all services performed by you for the
Company and any of its Affiliates and in consideration of your other agreements hereunder, you will be provided the following pay and benefits, subject to annual review by the board of 

 
directors of Roivant Sciences Ltd., the Company’s parent (“Parent”) or the compensation committee thereof (together with the board of directors of Parent, the
“Committee”): 
 (a)    Base Salary. You will be paid a base salary or similar
compensation at the rate of $350,000 per year, payable in accordance with the regular payroll practices of the Company and subject to increase from time to time by the Committee in its discretion (as adjusted, from time to time, the “Base
Salary”). 
 (b)    Bonus Compensation. For each fiscal year completed during your
employment under this Agreement, you will be entitled to an annual bonus to the extent earned hereunder (“Annual Bonus”). Your target Annual Bonus will be 100% of your Base Salary; provided, that you will have the opportunity
to earn an Annual Bonus in excess of 100% of your Base Salary, with the actual amount of any such Annual Bonus being determined by the Committee in good faith. Bonuses are deemed earned (and thus, no longer subject to any other conditions) on the
last day of the applicable fiscal year of the Company; provided, that you are employed by the Company as of such date. The Company will pay such bonus no later than April 30th of the year
following the end of the Company’s fiscal year. 
 (c)    Benefits. You will be entitled to
participate in all employee benefit plans from time to time in effect for employees of the Company generally, except to the extent such plans are duplicative of benefits otherwise provided you under this Agreement (e.g., a severance pay plan). Your
participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. You will be entitled to not less than four (4) weeks of vacation each year, in addition to sick leave and observed holidays
in accordance with the policies and practices with respect to executives of the Company. Vacation may be taken at such times and intervals as you shall determine, subject to the business needs of the Company. 

(d)    Existing Letter Agreements. Your rights and obligations under your four letter agreements
with the Company dated July 19, 2019, November 23, 2020, and March 2, 2021 (of which there are two) shall continue in full force and effect to the extent of, and in accordance with, the terms and conditions contained therein. 

(e)    Business Expenses. You will be paid or reimbursed for all reasonable, out of pocket expenses
incurred or paid by you attendant to the performance of your duties and responsibilities for the Company and its Affiliates, including, without limitation, for reasonable travel and accommodations on behalf of the Company and its Affiliates. The
Company agrees to reimburse you for all such expenses or payments not later than thirty (30) days after receipts for such expense or payment were submitted for payment or reimbursement in accordance with the Company’s policies. 

(f)    Acknowledgement and Waiver. By executing this Agreement, effective as of the Effective Date,
you acknowledge that you have received all compensation and benefits owed to you under the Prior Agreement, and you fully and forever waive and release the Company and its Affiliates from any and all claims or liabilities relating to any amount of
compensation or benefits contemplated under the Prior Agreement. 
 3.     Confidential Information and Restricted
Activities. 
 (a)    Confidential Information. During the course of your employment with the
Company, you will learn of Confidential Information, as defined below, and you may develop Confidential Information on behalf of the Company and its Affiliates. You agree that other than on behalf of the Company, you will not use or disclose to any
Person any Confidential Information obtained by you incident to your employment or any other association with the Company or its Affiliates, except (i) as required by applicable law, (ii) with prior written permission from the Board, or
(iii) as reasonably necessary to enforce the terms of this Agreement or the Shareholders Agreement, provided that you take reasonable steps to preserve the confidentiality of the Confidential Information such as by filing the Confidential
Information under seal. You agree that this restriction shall continue to apply during your employment and thereafter, regardless of the reason for such termination. 

  
 2 

 (b)    Protection of Documents. All documents,
records and files, in any media of whatever kind and description, relating to the business, present or otherwise, of the Company or any of its Affiliates, and any copies, in whole or in part, thereof (the “Documents”), whether or
not prepared by you, shall be the sole and exclusive property of the Company and/or its Affiliates. You agree to safeguard all Documents and to surrender to the Company, at the time your employment terminates or at such earlier time or times as the
Board or its designee may request in writing, all Documents then in your possession or under your control. You also agree to disclose to the Company, at the time your employment terminates or at such earlier time or times as the Board or its
designee may request in writing, all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information which you have password-protected on any computer equipment, network or system of the Company or
any of its Affiliates. 
 (c)    Assignment of Rights to Intellectual Property. All Intellectual
Property (as defined below) discovered, developed, or learned by you in whole or in part during your employment with the Company are the sole and absolute property of the Company or its Affiliates. You shall promptly and fully disclose all
Intellectual Property to the Company or its Affiliates. You hereby assign and agree to assign to the Company or its Affiliates (or as otherwise directed by the Company or its Affiliates) your full right, title and interest in and to all Intellectual
Property. You agree to execute any and all applications for domestic and foreign patents, copyrights or other proprietary rights and to do such other acts (including without limitation the execution and delivery of instruments of further assurance
or confirmation) reasonably requested by the Company and/or Parent to assign the Intellectual Property to the Company or its Affiliates and to permit the Company or its Affiliates to enforce any patents, copyrights or other proprietary rights to the
Intellectual Property. All copyrightable works that you create during your employment shall be considered “work made for hire” and shall, upon creation, be owned exclusively by the Company or its Affiliates. Any copyrightable work created
by you that does not directly or indirectly relate to the Company’s business is exempt from the foregoing. 

(d)    Restricted Activities. You agree that the following restrictions on your activities during
and after your employment are necessary to protect the good will, Confidential Information, trade secrets and other legitimate interests of the Company and its Affiliates: 

(i)    During the Restricted Period (as defined below), you shall not, directly or indirectly, whether as
owner, partner, investor, consultant, agent, employee, co–venturer or otherwise, engage in a Competitive Business (as defined below) anywhere in North America, Central America, South America, and their respective adjacent islands, Western
Europe, or Asia. Notwithstanding the foregoing, your ownership as a passive investor of five percent (5%) or less of the outstanding securities of any class of any publicly-traded securities of any such company shall not, by itself, be considered to
be competition with the Company or any of its subsidiaries or Affiliates. 
 (ii)    During the
Restricted Period, you shall not directly or indirectly, other than on the Company’s behalf (a) solicit or encourage any customer, prospective customer, supplier, licensor, lessor or other business relation of the Company or any of its
Affiliates to terminate or diminish its relationship with any of them; or (b) seek to persuade any customer, prospective customer, supplier, licensor, lessor or other business relation of the Company or any of its Affiliates to conduct with any
Person any business or activity which such customer, prospective customer, supplier, licensor, lessor or other business relation of the Company or any of its Affiliates conducts or could conduct with the Company or with any of its Affiliates;
provided, however, that these restrictions shall apply only with respect to those Persons who (x) are or have been a customer, supplier, licensor, lessor or other business relation of the Company or of any of its Affiliates at any time
within the immediately preceding one (1) year period of the date of your employment termination, or (y) whose business has been solicited on behalf of the 

  
 3 

 
Company or any of its Affiliates by any of their officers, employees or agents, other than by form letter, blanket mailing or published advertisement, at any time within the immediately preceding
one (1) year period of the date of your employment termination. 
 (iii)    During the Restricted
Period, you shall not, and shall not assist any other Person to, directly or indirectly, other than on behalf of the Company or Parent (a) hire or solicit for hire any employee of the Company or any of its Affiliates, or seek to persuade any
employee of the Company or any of its Affiliates to discontinue employment or (b) solicit or encourage any independent contractor providing services to the Company or any of its Affiliates to terminate or diminish its relationship with them.
For the purposes of this Agreement, an “employee” or an “independent contractor” of the Company or any of its Affiliates is any person who was such at any time within the immediately preceding one (1) year
period of the date of your employment termination. 
 (iv)    You agree not to make any public statement
disparaging the Company, its Affiliates or any of their respective officers, directors, employees, shareholders, agents or products in any manner that is reasonably likely to be harmful to the business reputation of the Company or any of its
Affiliates. The Company agrees that the executive officers of the Company or its Affiliates as of the date of termination and the members of the Board as of the date of termination will not, while employed by the Company or its Affiliates or serving
as a director of the Company or its Affiliates, as the case may be, make any public statement disparaging you in any manner that is reasonably likely to be harmful to your business reputation. Notwithstanding anything to the contrary in this
subsection, either party may make any statement necessary to respond to any government investigation, to comply with any court, legal or regulatory order or other requirement, or to comply with any subpoena. 

(e)    Personal Views. At all times during your employment with the Company, in connection with
(x) any Permitted Activities in which you engage or (y) any statement or other communication by you (or any entity you control) to any third party, reporter, author, producer or similar person or entity or to any general public media in
any form (including, without limitation, books, blogs, editorials, articles or writings of any other kind, film, videotape, audio tape, computer/internet format, podcast or any other medium) that is not made in furtherance of your duties and
responsibilities to the Company and its Affiliates hereunder, you agree that: 
 (i)    you will not
(A) affirmatively attribute any of your own personal views or opinions to the Company or any of its Affiliates nor (B) affirmatively portray yourself as acting on behalf of, or otherwise representing the views or interests of, the Company
and its Affiliates in such capacity or otherwise in connection therewith; 
 (ii)    you will use
reasonable efforts to cause any third-party with whom you are engaged not to take any of the actions described in sub-clauses (A) and (B) of clause (i) above; and 

(iii)    if it is reasonably certain that your personal views or opinions would be attributed to the
Company and its Affiliates in any written publication (including electronic publication), including, without limitation, books, blogs, editorials, articles or writings of any other kind, then you will use reasonable efforts to cause the inclusion of
a disclaimer that such views or opinions do not represent the views or opinions of the Company and its Affiliates. 

(f)    Whistleblower Protections. You have the right under federal law to certain protections for
cooperating with or reporting legal violations to the Securities and Exchange Commission (the “SEC”) and/or its Office of the Whistleblower, as well as certain other governmental entities and self-regulatory organizations. As
such, nothing in this Agreement or otherwise prohibits or limits you from disclosing this Agreement to, or from cooperating with or reporting violations to or initiating communications with, the SEC or any other such governmental

  
 4 

 
entity or self-regulatory organization, and you may do so without notifying the Company. Neither the Company nor any of its subsidiaries or affiliates may retaliate against you for any of
these activities, and nothing in this Agreement or otherwise require you to waive any monetary award or other payment that you might become entitled to from the SEC or any other governmental entity or self-regulatory organization. Moreover,
nothing in this Agreement or otherwise prohibits you from notifying the Company that you will make a report or disclosure to law enforcement.

(g)    Defend Trade Secrets Act. Notwithstanding anything to the contrary in this Agreement or
otherwise, as provided for in the Defend Trade Secrets Act of 2016 (18 U.S.C. § 1833(b)), you will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made
(A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a
complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Without limiting the foregoing, if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may
disclose the trade secret to your attorney and use the trade secret information in the court proceeding, if you (x) file any document containing the trade secret under seal, and (y) do not disclose the trade secret, except pursuant to
court order. 
 (h)    Acknowledgement; Enforceability. In signing this Agreement, you give the
Company assurance that you have carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on you under this Section 3. You agree without reservation that these restraints are necessary for
the reasonable and proper protection of the Company and its Affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. Without limiting the rights of the Company to
pursue any other legal and/or equitable remedies available to them for any breach by you of the covenants contained in this Section 3, you acknowledge that a breach of those covenants would cause a loss to the Company for
which they could not reasonably or adequately be compensated by damages in an action at law, that remedies other than injunctive relief could not fully compensate the Company for a breach of those covenants and that, accordingly, the Company shall
be entitled to injunctive relief to prevent any breach or continuing breaches of your covenants as set forth in this Section 3 without the need to post a bond. You and the Company further agree that, in the event that any
provision of this Section 3 is determined by any court of competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of activities,
that provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law. 

4.    Termination of Employment. Your employment under this Agreement shall continue until terminated pursuant to
this Section 4. For the avoidance of doubt, any termination of your employment by the Company pursuant to this Section 4 shall constitute termination of your employment by the Company, and your
resignation for Good Reason (as defined below) shall constitute your resignation for Good Reason from the Company. 

(a)    By the Company For Cause. The Company may terminate your employment immediately for Cause
upon notice to you setting forth in reasonable detail the nature of the Cause. The following, as determined by the Board in its reasonable judgment and supported by objective evidence, shall constitute “Cause” for termination:
(i) embezzlement, theft or misappropriation of any property of the Company or its Affiliates; (ii) use of alcohol or illegal drugs that interferes with the performance of the your obligations to the Company or its Affiliates;
(iii) conviction of, or plea of guilty or no contest to, (A) a felony or (B) any crime involving moral turpitude, dishonesty or theft; or (iv) refusal to follow the reasonable and lawful directions of the Board after written
notice and failure to cure within 90 days after receipt of such written notice. 
 (b)    By the
Company Without Cause. The Company may terminate your employment without Cause, at any time, upon notice to you. 

  
 5 

 (c)    Resignation by You. You may terminate your
employment at any time upon thirty (30) days advance written notice to the Company. Should you give such notice, the Company may require you to relinquish your job duties and responsibilities and no longer come into the Company’s offices
for some or all of the notice period; provided, that the Company continues to pay you your regular salary and maintain your Company employment benefits through the end of the notice period. 

(d)    Death and Disability. Your employment hereunder shall automatically terminate in the event of
your death during employment. In the event you become disabled during employment and, as a result, are unable to continue to perform substantially your duties and responsibilities under this Agreement, either with or without reasonable
accommodation, the Company will continue to pay you your Base Salary and to provide you benefits in accordance with Section 2(c) above, to the extent permitted by plan terms, for up to 12 weeks of disability during any
period of 365 consecutive calendar days. If you are unable to return to work after 12 weeks of disability, the Company may terminate your employment, upon 30 days’ prior written notice to you. 

(e)    Good Reason. You may terminate your employment with the Company for Good Reason upon prior
written notice to the Company setting forth in reasonable detail the nature of the Good Reason. For purposes of this Agreement, “Good Reason” means, without your written consent, a change in your title with the Company to other than
“Chairman” or “Executive Chairman” of the Company; provided, however, that such event shall not constitute Good Reason unless and until you have provided the Company with written notice setting forth in reasonable detail the
nature of the Good Reason and the Company has not cured such event within thirty (30) days after receipt of such notice. 

5.    Other Matters Related to Termination. 

(a)    Final Compensation. In the event of termination of your employment with the Company, however
occurring, you shall be paid: (i) your Base Salary for the final payroll period of your employment, through the date your employment terminates; (ii) compensation at the rate of your Base Salary for any vacation time earned but not used as
of the date your employment terminates; (iii) your Annual Bonus earned but not yet paid; and (iv) reimbursement for business expenses incurred by you but not yet paid to you as of the date your employment terminates; provided you submit
all expenses and supporting documentation required within 60 days of the date your employment terminates, and provided further that such expenses are reimbursable under the Company’s policies as then in effect (all of the foregoing,
“Final Compensation”). 
 (b)    Severance Payments. In the event of your
separation from service in connection with any termination of your employment pursuant to Sections 4(b) or 4(e) above, you will be paid, in addition to Final Compensation, and only to the extent that you continuously comply with
your obligations under Section 3 hereof (i) your Base Salary for the period of two (2) years from the date of termination and (ii) a single lump-sum payment equal to
the average of your target Annual Bonus for the past three (3) years of your employment with the Company (collectively, the “Severance Payments”); provided, however, that you sign within 60 calendar days after the
date of termination a release in the same or similar form of Exhibit A hereto. 

(c)    Conditions to and Timing of Severance Payments. Any salary component of the Severance
Payments to which you are entitled will be provided in the form of salary continuation, payable in accordance with the normal payroll practices of the Company or an Affiliate, and the first payment will be made on the next regular pay-day following the expiration of 60 calendar days from the date of termination; but that first payment shall be retroactive to the date of termination. Any bonus component of the Severance Payments to which you
are entitled will be made on the date on the next regular pay-day following the expiration of 60 calendar days from the date of termination. 

  
 6 

 (d)    Benefits Termination. Except for any right
you may have under the federal law known as “COBRA” to continue participation in the Company group health and dental plans, your participation in all employee benefit plans shall terminate in accordance with the terms of the applicable
benefit plans based on the date of termination of your employment, without regard to any continuation of base salary or other payment to you following termination and you shall not be eligible to earn vacation or other paid time off following the
termination of your employment. In the event of your separation from service in connection with any termination of your employment pursuant to Sections 4(b) or 4(e) above, and provided that you timely sign the general release
referenced in Section 5(b), above, the Company shall pay or reimburse you for the difference between the COBRA premiums associated with continued group health and dental plan coverage in which you were enrolled as of the date of your
employment termination and the premiums that you would have paid had you remained employed at the Company until the earlier of eighteen (18) months from the date of the termination of your employment, or until you become eligible to be covered
under a subsequent employer’s group health insurance plan. You agree to provide the Company with written notice of your eligibility to be covered under a subsequent employer’s group health insurance plan no later than five
(5) business days after you become eligible for such coverage. 
 (e)    Equity Compensation.
With respect your equity incentive awards that were granted prior to March 31, 2021 under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (as amended or restated from time to time, the “RSL Equity
Plan”) (such awards, the “Eligible Equity Awards”): 
 (i)    in the event of a
termination of your employment (x) pursuant to Sections 4(b) or 4(e) or (y) upon mutual agreement between you and the Company that it would be in the best interests of the Company to terminate your employment, all
service-based vesting conditions (including any requirement that you be employed at the time of achievement of an applicable performance-based vesting condition) with respect to one-hundred percent (100%) of
your Eligible Equity Awards that are outstanding as of the date of such termination of your employment shall be immediately waived; and 

(ii)    in the event of a termination of your employment pursuant to
Section 4(d), all service-based vesting conditions (including any requirement that you be employed at the time of achievement of an applicable performance-based vesting condition) with respect to fifty percent (50%) of your
Eligible Equity Awards that are outstanding as of the date of such termination of your employment shall be immediately waived; 

provided, in the case of each of clauses (i) and (ii) above, that (A) such Eligible Equity Awards shall remain subject to any
additional vesting conditions or other terms and conditions otherwise applicable to such Eligible Equity Awards, including the achievement of any applicable performance-based vesting conditions and any condition requiring the occurrence of a
liquidity event and (B) you sign within 60 calendar days after the applicable date of termination a release in the same or similar form of Exhibit A hereto (collectively, the “Equity Acceleration Benefits”). You and
Parent agree that, notwithstanding anything to the contrary set forth in the RSL Equity Plan or any applicable award agreement thereunder, effective as of the Effective Date, the Eligible Equity Awards (including any award agreement evidencing such
awards) shall be deemed automatically amended to provide for the Equity Acceleration Benefits in accordance with, and subject to the terms of, this Section 5(e), without any further action necessary by you or Parent. Each
outstanding equity award (vested or unvested) held by you other than the Eligible Equity Awards shall be governed by the terms of the applicable award agreement and plan under which such award was granted. 

(f)    Survival. Provisions of this Agreement shall survive any termination of employment if so
provided in this Agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation your obligations under Section 3 of this Agreement. The obligation of the
Company or an Affiliate to make payments to 

  
 7 

 
you under Section 5(b), and your right to retain the same, are expressly conditioned upon your continued full performance of your obligations under
Section 3 hereof. Upon termination by either you or the Company, all rights, duties and obligations of you (on one hand) and the Company and its Affiliates (on the other hand) to each other shall cease, except as otherwise
expressly provided in this Agreement. 
 6.    Timing of Payments and Section 409A. 

(a)    Notwithstanding anything to the contrary in this Agreement, if at the time your employment
terminates, you are a “specified employee,” as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this provision) be payable within six (6) months following
the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month period or, if earlier, upon your death; except (A) to the extent of amounts that do not constitute a deferral of
compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation by reason of the safe harbor set forth in
Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable good faith discretion); (B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5); or (C) other amounts or benefits that are not subject to the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). 

(b)    For purposes of this Agreement, all references to “termination of employment” and
correlative phrases shall be construed to require a “separation from service” (as defined in Section 1.409A1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term “specified
employee” means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i). 

(c)    Each payment made under this Agreement shall be treated as a separate payment and the right to a
series of installment payments under this Agreement is to be treated as a right to a series of separate payments. 

7.    Section 280G. If you would be entitled to payments or benefits under this Agreement or under any other plan,
program, agreement or arrangement that would constitute “parachute payments” as defined in Section 280G of the Code and could result in any such payment or benefit being subject to an excise tax under Section 4999 of the Code,
the present value of your payments and benefits will be reduced by the minimum amount necessary such that the aggregate present value of such payments and benefits do not trigger the excise tax; provided, however, no such reductions shall be given
effect if you would be entitled to greater payments and benefits on an after-tax basis (taking into account the excise tax imposed pursuant to Section 4999 of the Code, any tax imposed by any comparable
provision of state law, and any applicable federal, state and local income and employment taxes) than if such reductions were to be implemented. If payments or benefits are to be reduced, any such reduction in payments and/or benefits shall be made
in accordance with Section 409A of the Code and shall occur in the manner that results in the greatest economic benefit to you as determined by the Company’s independent accountants. All determinations in applying the foregoing provisions
for purposes of the “golden parachute” rules under Sections 280G and 4999 of the Code will be made by the Company’s independent accountants and shall be final and binding on the parties. 

8.    Definitions. For purposes of this Agreement, the following definitions apply: 

“Affiliates” means all persons and entities directly or indirectly controlling, controlled by or under common control with
any of the Company or Parent, where control may be by management authority, equity interest or otherwise; provided that, any shareholder or other equity holder of Parent shall not be deemed an Affiliate of Parent or the Company for purposes of this
Agreement unless such holder owns more than 50% of the outstanding voting power of Parent. 
 “Competitive Business” means
any Person that is primarily engaged in drug development for profit; provided, that (a) if such Person has a market capitalization equal to or in excess of $10 billion (if 

  
 8 

 
such Person is a publicly-traded company) or annual revenue equal to or in excess of $1 billion (if such Person is not a publicly traded company), it shall not be considered a Competitive
Business provided that (i) you are not employed by such Person (whether directly or as a consultant) to perform services in a therapeutic area in which the Company or any of its Affiliates is developing drugs as of the date on which your
employment is terminated (a “Roivant Therapeutic Area”), and (ii) you provide written assurance to the Board that adequate steps have been taken by you and such Person that will effectively preclude you from performing services
in a Roivant Therapeutic Area during the Restricted Period; and (b) if such Person has a market capitalization of less than $10 billion (if such Person is a publicly-traded company) or annual revenue of less than $1 billion (if such
Person is not a publicly traded company), it shall not be considered a Competitive Business, unless (i) such Person’s primary business strategy is the acquisition of drug candidates from other Persons, or (ii) such Person’s
primary drug development candidates are in a Roivant Therapeutic Area. 
 “Confidential Information” means any and all
information, data, formulas and related concepts, chemical compounds, business plans (both current and under development), clinical and regulatory plans, filings and protocols, customer lists, promotion and marketing programs, trade secrets,
information relating to development programs, costs, revenues, marketing, investments, sales activities, promotions, credit and financial data, manufacturing processes, supply arrangements, financing methods, plans, and personnel information of the
Company and its Affiliates. Confidential Information also includes any information received by the Company or any of its Affiliates from any Person with any understanding, express or implied, that it will not be disclosed. Confidential Information
does not include information that enters the public domain other than through your breach of your obligations under this Agreement or any other Person’s breach of an obligation not to disclose such information. 

“Intellectual Property” means inventions, discoveries, developments, methods, processes, compositions, works, concepts and
ideas (whether or not patentable or copyrightable or constituting trade secrets) conceived, made, created, developed or reduced to practice by you (whether alone or with others, whether or not during normal business hours or on or off the
Company’s or any of its Affiliates’ premises) during your employment that relate to the business of the Company or any of its Affiliates. Notwithstanding the above, Intellectual Property does not include an invention for which no
confidential, proprietary, or trade secret information of the Company or its Affiliates was used and which was developed entirely on your own time, unless the invention (a) relates to the business of the Company or its Affiliates or to their
actual or demonstrably anticipated research and development, or (b) results from any work performed by you for the Company or its Affiliates. 

“Person” means an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust
or any other entity or organization, other than the Company or any of its Affiliates. 
 “Restricted Period” means during
your employment and the eighteen (18) month period immediately following the later of the termination of your employment with the Company; provided that with respect to the application of Section 3(d)(i)
only, “Restricted Period” means during your employment and the twelve (12) month period immediately following the date your employment is terminated if and only if your employment is terminated without “Cause” or you
resign for “Good Reason” in accordance with Section 4 above 
 “Shareholders Agreement”
means that certain Fifth Amended & Restated Shareholders Agreement of Parent, dated as of March 26, 2020, among Parent and the shareholders from time to time party thereto. 

9.    Mediation and Waiver of Jury Trial. Other than disputes involving the covenants and obligations set forth in
Section 3 above which may be filed directly in a court of law, you and the Company agree that all other disputes and claims of any nature that you may have against the Company, including, but not limited to, all statutory,
contractual, and common law claims (including all employment discrimination claims), will be submitted exclusively first to mandatory mediation in New York, New York, or at another mutually agreed-upon location, under the rules of Judicial
Arbitration and Mediation Services or under such other rules or under the auspices of such other organization as the parties may mutually agree. All information regarding the dispute or claim or mediation proceeding, including any

  
 9 

 
mediation settlement shall not be disclosed by you, the Company or any mediator to any third party without the written consent of you and the Board. In the event that mediation does not resolve
any dispute that you have with the Company and you proceed to file a complaint in court, YOU HEREBY WAIVE ANY RIGHT TO A JURY TRIAL OF THAT DISPUTE. You further agree that any such complaint initiated by you against the Company must be filed
in a state or federal court located in the City of New York, Borough of Manhattan, you irrevocably consent to the personal jurisdiction and venue of such courts, and you waive all objections thereto. 

10.    Withholding. All payments made by the Company or an Affiliate under this Agreement shall be reduced by any
tax or other amounts required to be withheld by the Company or such Affiliate under applicable law. 

11.    Assignment. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by
operation of law or otherwise, without the prior written consent of the other; provided, however, the Company may assign its rights and obligations under this Agreement without your consent to any Person with whom the Company shall
hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you, the Company and each of its
respective successors, executors, administrators, heirs and permitted assigns. 
 12.    Severability. If any
portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

13.    Representations and Warranties by You. You hereby represent and warrant to the Company as follows: 

(a)    Neither the execution or delivery of this Agreement nor the performance by you of your duties and
other obligations hereunder violates or will violate any statute, law, determination or award, or conflicts with or constitutes a default or breach of any covenant or obligation under (whether immediately, upon the giving of notice or lapse of time
or both) any prior employment agreement, contract, or other instrument to which you are a party or by which you are bound. 

(b)    You have the full right, power and legal capacity to enter and deliver this Agreement and to perform
your duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of you and is enforceable against you in accordance with its terms. No approvals or consents of any persons or entities are required for
you to execute and deliver this Agreement or perform your duties and other obligations hereunder. 

14.    Miscellaneous. As of the Effective Date, this Agreement, along with the Letter Agreement and the letter
agreements described in Section 2(d), set forth the entire agreement among you and the Company and supersede all other prior and contemporaneous communications, agreements and understandings, written or oral, with respect
to the terms and conditions of your employment (including the Prior Agreement). For the avoidance of doubt, the Prior Agreement remains in effect for periods prior to the Effective Date. This Agreement may not be modified or amended, and no breach
shall be deemed to be waived, unless agreed to in writing by you and an expressly authorized representative of the Board. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of
any provision of this Agreement. This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument. This Agreement shall be governed and construed in
accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof that would result in the application of the law of any other jurisdiction. The Company (a) acknowledges that it has, by separate
written instrument, irrevocably designated and appointed Corporation Service Company (“CSC”), 1180 Avenue of the Americas, Suite 210, New York, New York 10036-8401 as its authorized agent upon which process

  
 10 

 
may be served in any suit or proceeding arising out of or relating to this Agreement and acknowledges that CSC has accepted such designation and (b) agrees that service of process upon CSC,
and written notice of said service to the Company in the manner provided in Section 22 of the Shareholders Agreement shall be deemed in every respect effective service of process upon the Company in any such suit or proceeding. the Company
further agrees to take any and all action, including the execution and filing of any and all such documents and instruments, as may be necessary to continue such designation and appointment of CSC in full force and effect so long as any of this
Agreement shall be in effect. 
 15.    Notices. Any notices provided for in this Agreement shall be in writing
and shall be effective when delivered in person or one (1) business day after being deposited with an internationally recognized overnight courier addressed to you at your last known address on the books of the Company or, in the case of the
Company, to it at its principal place of business, attention of the Chair of the Board, or to such other address as either party may specify by notice to the other actually received. 

16.    Indemnification. The Company shall indemnify you to the maximum extent permitted by law in respect of any
claim, investigation, suit or dispute brought against you because you serve as an officer of the Company, and the Company agrees to advance your reasonable expenses incurred therewith upon you executing an undertaking agreeing to repay any such
advances if you are ultimately found not to have been entitled to such indemnification. The Company shall not be obligated to indemnify you if a court of competent jurisdiction finds your conduct to have constituted gross negligence, willful
misconduct, fraud, or criminal conduct in performing or failing to perform any duties and responsibilities under this Agreement. Without limiting the generality of the foregoing, your right to indemnification, as provided in (i) the Roivant
Sciences Ltd. Amended & Restated Indemnity Agreement, dated as of February 10, 2019, and (ii) the Tax Indemnity and Support Agreement, dated as of October 31, 2019, between you, the Company and Parent shall each continue in
full force and effect to the extent of, and in accordance with, the terms and conditions contained therein. 
 If the foregoing is
acceptable to you, please sign this Agreement in the space provided and return it to me at your earliest convenience. At the time you sign and return it, this Agreement will take effect as a binding agreement between you and the Company on the basis
set forth above. 
 *    *    * 

  
 11 

 
			
	Sincerely yours,
	
	Roivant Sciences, Inc.
		
	By:	 	  

		 	Name:
		 	Title:
	
	For purposes of Section 5(e) of this Agreement:
	
	Roivant Sciences Ltd.
		
	By:	 	  

		 	Name:
		 	Title:

  

			
	Accepted and Agreed
		
	By:	 	  

		 	Name:    Vivek Ramaswamy
		 	Date:      May 14, 2021

 Exhibit A 

GENERAL RELEASE 

I, Vivek Ramaswamy, in consideration of and subject to the performance by the Company, of its obligations under Sections 5(b),
5(d) and 5(e), as applicable, of the Amended and Restated Employment Agreement, dated May 14, 2021 (the “Agreement”), do hereby release and forever discharge as of the date hereof the Company, its Affiliates, and
all present, former and future respective direct and indirect owners, directors, officers, agents, representatives, employees, successors and assigns of each of them (collectively, the “Released Parties”) to the extent provided
herein (this “General Release”). The Released Parties are intended third-party beneficiaries of this General Release, and this General Release may be enforced by each of them in accordance with the terms hereof in respect of the
rights granted to such Released Parties hereunder. Terms used herein but not otherwise defined shall have the meanings given to them in the Agreement. 

1.    I understand that any payments or benefits paid or granted to me under Sections 5(b), 5(d) and
5(e), as applicable, of the Agreement represent, in part, consideration for signing this General Release and are not salary, wages or benefits to which I was already entitled. I understand and agree that I will not receive the payments and
benefits specified in Sections 5(b), 5(d) and 5(e), as applicable, of the Agreement unless I execute this General Release and do not revoke this General Release within the time period permitted hereafter or breach this General
Release. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates. 

2.    Except as provided in Paragraph 4 below, and except for Section 5 (Other Matters Related
to Termination) and Section 16 (Indemnification) of the Agreement, I knowingly and voluntarily (for myself, my heirs, executors, administrators and assigns) release and forever discharge the Company and the other Released
Parties from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and
attorneys’ fees, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date that this General Release becomes effective and enforceable) and whether known or unknown, suspected, or claimed against the
Company and/or any of the Released Parties which I, or any of my heirs, executors, administrators or assigns, ever had, now have, or hereafter may have, by reason of any matter, cause, or thing whatsoever, from the beginning of my initial dealings
with the Company to the date of this General Release, and particularly, but without limitation of the foregoing general terms, any claims arising from or relating in any way to my employment relationship with the Company, the terms and conditions of
that employment relationship, and the termination of that employment relationship (including, but not limited to, any allegation, claim or violation, arising under: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991;
the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act of 1993; the
Worker Adjustment Retraining and Notification Act; the Employee Retirement Income Security Act of 1974; any applicable Executive Order Programs; or their state or local counterparts; or under any other international, federal, state or local civil or
human rights law, or under any other international, federal, state or local regulation or ordinance; or under any public policy, contract or tort, or under common law; or arising under any policies, practices or procedures of the Company or any of
its Affiliates; or any claim for wrongful discharge, breach of contract, infliction of emotional distress, defamation; or any claim for costs, fees, or other expenses, including attorneys’ fees incurred in these matters) (all of the foregoing
collectively referred to herein as the “Claims”). I understand and intend that this General 
 Release constitutes a
general release of all claims and that no reference herein to a specific form of claim, statute or type of relief is intended to limit the scope of this General Release. 

3.    I represent that I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter
covered by Paragraph 2 above. 

  
 A-1 

 4.    I agree that this General Release does not waive or release any
rights or claims that I may have under the Age Discrimination in Employment Act of 1967 which arise after the date I execute this General Release. I acknowledge and agree that my separation from employment with the Company in compliance with the
terms of the Agreement shall not serve as the basis for any claim or action (including, without limitation, any claim under the Age Discrimination in Employment Act of 1967). 

5.    I agree that I hereby waive all rights to sue or obtain equitable, remedial or punitive relief from any or all
Released Parties of any kind whatsoever, including, without limitation, reinstatement, back pay, front pay, and any form of injunctive relief. Notwithstanding the foregoing, I acknowledge that I am not waiving and am not being required to waive any
right that cannot be waived under law, including the right to file an administrative charge or participate in an administrative investigation or proceeding; provided, however, that I disclaim and waive any right to share or participate in any
monetary award resulting from the prosecution of such charge or investigation or proceeding. 
 6.    In signing this
General Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that this General Release shall be given full force and effect according to each
and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding any international, state or local statute that expressly limits the effectiveness of a general release of unknown, unsuspected
and unanticipated Claims), if any, as well as those relating to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver is an essential and material term of this General Release and that without such waiver the
Company would not have agreed to the terms of the Agreement. I further agree that in the event that I should bring a Claim seeking damages against the Company, or in the event that I should seek to recover against the Company in any Claim brought by
a governmental agency on my behalf, this General Release shall serve as a complete defense to such Claims to the maximum extent permitted by law. I further agree that I am not aware of any pending claim, or of any facts that could give rise to a
claim, of the type described in Paragraph 2 as of the execution of this General Release. 
 7.    I agree that neither
this General Release, nor the furnishing of the consideration for this General Release, shall be deemed or construed at any time to be an admission by the Company, any Released Party or myself of any improper or unlawful conduct. 

8.    I do not release any Claim I have to workers’ compensation benefits or vested benefits under any pension plan,
employee benefit plan or any other plan or program of the Company. 
 9.    I agree that this General Release and the
Agreement are confidential and agree not to disclose any information regarding the terms of this General Release or the Agreement, except to my immediate family and any tax, legal or other counsel that I have consulted regarding the meaning or
effect hereof or as required by law, and I will instruct each of the foregoing not to disclose the same to anyone. The Company agrees to disclose any such information only to those of its employees who have a need to know, tax, legal or other
counsel of the Company, or as required by law. 
 10.    Any non-disclosure
provision in this General Release does not prohibit or restrict me (or my attorney) from responding to any inquiry about this General Release or its underlying facts and circumstances by the Securities and Exchange Commission (SEC), the Financial
Industry Regulatory Authority (FINRA), or any other self-regulatory organization or governmental entity, or from reporting a violation of law or making a disclosure that is protected under the whistleblower protections of applicable law. 

11.    I also agree to reasonably cooperate with the Company and any of the Released Parties in connection with any
internal review or investigations, any regulatory or enforcement inquiries or investigation, and the defense or prosecution of any claims or actions now in existence or which may arise in the future in connection with, against or on behalf of the
Company and any of the Released Parties. My reasonable cooperation shall include, but not be limited to, my being available to meet with, be interviewed by or otherwise assist Company counsel in connection with an internal review or investigation, a
regulatory or enforcement inquiry or investigation, to prepare for trial or discovery or a regulatory, enforcement or 

  
 A-2 

 
administrative proceeding or alternative dispute resolution process and to act as a witness when requested by the Company at reasonable times designated by the Company. The Company will provide
reasonable notice of the need for my services and will use reasonable efforts to accommodate my personal and professional schedule in scheduling my services. Moreover, unless otherwise prohibited by law, I agree to promptly notify the Legal
Department of the Company if I am asked by any person, entity or agency to assist, testify or provide information in any such proceeding or investigation. If I am not legally permitted to provide such notice, I agree that I will request that the
person, entity or agency seeking assistance, testimony or information provide notice consistent with this Paragraph. To the extent I incur out-of-pocket expenses (such
as postage costs or telephone charges) in assisting the Company or any Affiliate at its request, the Company will mail me a reimbursement check for those expenses within 30 days after it receives my request for payment, along with reasonably
satisfactory written substantiation of the claimed expenses. My obligations under this Paragraph 11 will end upon the expiration of the applicable statute of limitations period for the particular claim provided that a timely claim has not been
asserted. In the event that a timely claim is asserted, my obligations will continue until the claim is resolved. 

12.    I hereby acknowledge that certain provisions of the Agreement, including Section 3
thereof shall survive my execution of this General Release. 
 13.    I acknowledge that I may hereafter discover Claims
or facts in addition to or different than those which I now know or believe to exist with respect to the subject matter of the release set forth in Paragraph 2 above and which, if known or suspected at the time of entering into this General Release,
may have materially affected this General Release and my decision to enter into it. 
 14.    Notwithstanding anything
in this General Release to the contrary, this General Release shall not relinquish, diminish, or in any way affect any rights or claims arising out of any breach by the Company of the Agreement after the date hereof. 

15.    Whenever possible, each provision of this General Release shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this General Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall
not affect any other provision or any other jurisdiction, but this General Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. This General
Release constitutes the complete and entire agreement and understanding among the parties, and supersedes any and all prior or contemporaneous agreements, commitments, understandings or arrangements, whether written or oral, between or among any of
the parties, in each case concerning the subject matter hereof. 
 BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT: 

 

	 	(i)	 I HAVE READ IT CAREFULLY; 

 

	 	(ii)	 I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO,
RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED, THE EQUAL PAY ACT OF 1963, THE AMERICANS WITH DISABILITIES ACT OF 1990, AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT
OF 1974, AS AMENDED; 

  

	 	(iii)	 I VOLUNTARILY CONSENT TO EVERYTHING IN IT; 

 

	 	(iv)	 I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR, AFTER CAREFUL
READING AND CONSIDERATION, I HAVE CHOSEN NOT TO DO SO OF MY OWN VOLITION; 

  

	 	(v)	 I HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS RELEASE TO CONSIDER IT AND THE CHANGES MADE
SINCE MY RECEIPT OF THIS RELEASE ARE NOT MATERIAL OR WERE MADE AT MY REQUEST AND WILL NOT RESTART THE REQUIRED 21-DAY PERIOD; 

  
 A-3 

	 	(vi)	 UNDERSTAND THAT I HAVE SEVEN (7) DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT AND THAT THIS
RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED; 

  

	 	(vii)	 I HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO
ADVISE ME WITH RESPECT TO IT; AND 

  

	 	(viii)	 I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY
AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME. 

  

					
	 SIGNED:

 
	  		  	 DATE:

 

  
 A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]